SEARCH

SEARCH BY CITATION

FilenameFormatSizeDescription
epi12242-sup-0001-DataS1.docxWord document116KData S1. Population and Methods (participants and interventions) and Results (study population).
epi12242-sup-0002-TableS1-S4.docxWord document102K

Table S1. Randomization table.

Table S2. Treatment allocations.

Table S3. Main demographic characteristics.

Table S4. Number of subjects (%) reporting treatment-emergent adverse events (TEAEs) following a repeated-dose regimen of eslicarbazepine acetate (ESL) and oxcarbazepine (OXC).

Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.